TBK1 (TANK-Binding Kinase 1, also known as NF-κB-activating kinase or NAK) is a 729-amino acid serine/threonine kinase that serves as a central regulator of multiple cellular signaling pathways including innate immunity, autophagy, and interferon responses. Originally characterized as a kinase involved in NF-κB activation and type I interferon induction, TBK1 has emerged as a critical player in neurodegenerative diseases. Heterozygous loss-of-function mutations in TBK1 cause familial amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD), establishing TBK1 haploinsufficiency as a key disease mechanism. [1][2][3]
TBK1 possesses a modular domain architecture enabling its diverse functions:
| Domain | Residues | Function |
|---|---|---|
| Kinase domain | 1-307 | Catalytic activity (S/T protein kinase) |
| Ubiquitin-like domain (ULD) | 308-383 | Substrate recognition, adaptive immunity |
| Coiled-coil 1 (CC1) | 400-450 | Dimerization, protein interaction |
| Coiled-coil 2 (CC2) | 450-500 | TBK1 complex formation |
| C-terminal | 500-729 | Binding partners, regulatory interactions |
TBK1 is a non-canonical IκB kinase (IKK) that phosphorylates multiple substrates in the innate immune response:
IRF3/IRF7 activation — TBK1 phosphorylates interferon regulatory factors 3 and 7, leading to type I interferon (IFN-α/β) induction. This is critical for antiviral immunity.
NF-κB signaling — TBK1 contributes to NF-κB activation through phosphorylation of IKKε and other components, promoting pro-inflammatory gene expression.
STING pathway — TBK1 is essential for STING (Stimulator of Interferon Genes) activation in response to cytosolic DNA, linking DNA sensing to interferon production.
MAVS phosphorylation — TBK1 phosphorylates Mitochondrial Antiviral Signaling protein, enhancing RIG-I mediated antiviral responses.
TBK1 plays a central role in selective autophagy:
p62/SQSTM1 phosphorylation — TBK1 phosphorylates p62 at S409, enhancing its ability to bind ubiquitinated cargo and form autophagosomes.
Mitophagy — TBK1 phosphorylates Parkin and OPTN, facilitating PINK1/Parkin-mediated mitophagy for mitochondrial quality control.
Xenophagy — TBK1 contributes to clearance of intracellular pathogens through autophagy.
Aggrephagy — TBK1-mediated p62 phosphorylation promotes clearance of protein aggregates, relevant to neurodegeneration.
Beyond immunity and autophagy, TBK1 regulates:
TBK1 mutations account for approximately 1-2% of familial ALS and ~1% of familial FTD cases:
| Mutation Type | Effect | Prevalence |
|---|---|---|
| Missense | Often loss-of-function | Most common |
| Truncating | Haploinsufficiency | ~30% of TBK1 cases |
| Splice site | Exon skipping | Less common |
| Frameshift | Premature termination | Variable |
TBK1 haploinsufficiency leads to disease through multiple mechanisms:
| Partner | Interaction | Disease Relevance |
|---|---|---|
| OPTN | Phosphorylation substrate | ALS mutant OPTN triggers |
| SQSTM1/p62 | Autophagy receptor | ALS/FTD aggregates |
| NDP52 | Selective autophagy receptor | Impaired in disease |
| TDP-43 (TDP-43) | Stress granule component | ALS/FTD pathology |
| IRF3 | Interferon signaling | Immune dysregulation |
While primarily associated with ALS/FTD, TBK1 dysfunction may contribute to AD pathogenesis:
Emerging evidence suggests TBK1 involvement in PD:
| Approach | Mechanism | Development Stage |
|---|---|---|
| TBK1 activators | Increase TBK1 activity | Preclinical |
| Small molecule modulators | Enhance function | Discovery |
| Gene therapy | Restore expression | Preclinical |
| Autophagy enhancers | Bypass TBK1 function | Preclinical |
| p62 activators | Compensate for TBK1 loss | Discovery |
Since TBK1 sits at the intersection of multiple pathways, therapeutic strategies include:
TBK1 plays a critical role in microglial biology:
Dysregulated TBK1 in microglia contributes to:
TBK1 haploinsufficiency intersects with TDP-43 proteinopathy:
Restoring TBK1 function or bypassing its deficiency may:
TBK1 levels may serve as disease biomarkers:
| Marker | Sample | Disease Relevance |
|---|---|---|
| TBK1 activity | CSF | ALS/FTD progression |
| p62 phosphorylation | Blood | Autophagy function |
| IFN signatures | Blood | Immune activation |
| Model | Application | Reference |
|---|---|---|
| TBK1 knockout mice | ALS/FTD modeling | Cirulli et al., 2015 |
| iPSC-derived neurons | Patient-specific | Freischmidt et al., 2015 |
| CRISPR models | Gene editing | Burns et al., 2018 |
TBK1 is a serine/threonine kinase that sits at the intersection of innate immunity, autophagy, and interferon signaling. Its haploinsufficiency causes familial ALS and FTD, making it a critical therapeutic target. The kinase's role in p62 phosphorylation and selective autophagy links it to protein aggregate clearance in multiple neurodegenerative diseases. Therapeutic strategies including TBK1 activators, gene therapy, and autophagy bypass approaches are under development. Understanding TBK1 biology continues to reveal connections between immunity, autophagy, and neurodegeneration.
TBK1 integrates signals from multiple pathways:
Cirulli ET, Lasseigne BN, Petrovski S, et al. Exome sequencing in ALS identifies risk genes and pathways. Science. 2015. ↩︎
Freischmidt A, Wieland T, Müller K, et al. Haploinsufficiency of TBK1 causes familial ALS and FTD. Nature Neuroscience. 2015. ↩︎
Burns TC, et al. TBK1 mutations in ALS/FTD: beyond autophagy. Nature Neuroscience. 2018. ↩︎
Li J, et al. TBK1 in neuroinflammation and neurodegenerative disease. Neuron. 2020. ↩︎
Oakes JA, et al. TBK1 and autophagy regulation in neurodegeneration. Journal of Cell Biology. 2017. ↩︎
Richter B, et al. TBK1 controls metabolic stress in neurons. Cell. 2016. ↩︎
Xu L, et al. TBK1 and the innate immune response in Alzheimer's disease. Journal of Neuroinflammation. 2021. ↩︎
Ikeda M, et al. TBK1 in microglia: immune regulation in the brain. Glia. 2020. ↩︎